Review



fibronectin  (Cytoskeleton Inc)


Bioz Verified Symbol Cytoskeleton Inc is a verified supplier
Bioz Manufacturer Symbol Cytoskeleton Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Cytoskeleton Inc fibronectin
    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of <t>fibronectin</t> in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .
    Fibronectin, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 61 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fnr02+a/Fibronectin+-+Green+fluorescent%2C+HiLyte+488/pmc13522766-74-0-6
    Average 95 stars, based on 61 article reviews
    fibronectin - by Bioz Stars, 2026-10
    95/100 stars

    Images

    1) Product Images from "EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation"

    Article Title: EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2026.102963

    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of fibronectin in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .
    Figure Legend Snippet: EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of fibronectin in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .

    Techniques Used: Expressing, RNA Sequencing, Cell Culture, Suspension, Control, Immunostaining, Degradation Assay, Fluorescence, Inhibition


    Figure Legend Snippet:

    Techniques Used: Control, Virus, Recombinant, Modification, Isolation, Proliferation Assay, Single Cell, Knockdown, Software

    Related Articles

    Saline:

    Article Title: Amyloid‐Based Albumin Hydrogels
    Article Snippet: Fibronectin HiLyte 488 , FFn , Cytoskeleton , FNR02‐A.



    Similar Products

    fibronectin  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc fibronectin
    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of <t>fibronectin</t> in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .
    Fibronectin, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fnr02+a/Fibronectin+-+Green+fluorescent%2C+HiLyte+488/pmc13522766-74-0-6
    Average 95 stars, based on 1 article reviews
    fibronectin - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    fibronectin - green fluorescent, hilyte 488  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc fibronectin - green fluorescent, hilyte 488
    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of <t>fibronectin</t> in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .
    Fibronectin Green Fluorescent, Hilyte 488, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fnr02+a/Fibronectin+-+Green+fluorescent%2C+HiLyte+488/custom%40fnr02%4042546699
    Average 95 stars, based on 1 article reviews
    fibronectin - green fluorescent, hilyte 488 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    fibronectin hilyte488  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc fibronectin hilyte488
    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of <t>fibronectin</t> in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .
    Fibronectin Hilyte488, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fnr02+a/Fibronectin+-+Green+fluorescent%2C+HiLyte+488/pm41906244-227-30-34
    Average 95 stars, based on 1 article reviews
    fibronectin hilyte488 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    fluorescent fibronectin  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc fluorescent fibronectin
    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of <t>fibronectin</t> in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .
    Fluorescent Fibronectin, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fnr02+a/Fibronectin+-+Green+fluorescent%2C+HiLyte+488/pm41063455-78-16-18
    Average 95 stars, based on 1 article reviews
    fluorescent fibronectin - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    fluorescent fibronectin fnr02 a  (Cytoskeleton Inc)
    95
    Cytoskeleton Inc fluorescent fibronectin fnr02 a
    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of <t>fibronectin</t> in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .
    Fluorescent Fibronectin Fnr02 A, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fnr02+a/Fibronectin+-+Green+fluorescent%2C+HiLyte+488/us12472286-411-28-31
    Average 95 stars, based on 1 article reviews
    fluorescent fibronectin fnr02 a - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of fibronectin in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .

    Journal: Cell Reports Medicine

    Article Title: EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation

    doi: 10.1016/j.xcrm.2026.102963

    Figure Lengend Snippet: EGFRi-CHI3L1 signaling inhibits cell clump formation and restores apicobasal polarity of donor RPE (A) Expression density maps of EGFR and CHI3L1 on UMAP projection of donor RPE cells, visualized using the inferno color scale. (B) Edge bundling network plot of genes correlated with CHI3L1 expression. (C) Edge bundling network plot of genes correlated with EGFR expression. (D) Schematic diagram of the experimental design for bulk RNA-seq. RPE cells were cultured under either adherent or suspension conditions and treated with DMSO (Control) or erlotinib (EGFRi), followed by transcriptomic profiling. (E) Venn diagram depicting the number of unique and overlapping differentially expressed genes (DEGs) among the treatment groups, color-coded as indicated. (F) Heatmap of DEGs identified from the four treatment comparisons, with expression Z scores colored red for upregulation and blue for downregulation. A select cluster of co-regulated genes (outlined) was subjected to gene set enrichment analysis, with significantly enriched biological terms and their corresponding p values displayed. (G) Representative z stack immunostaining images show the localization of ATP1A1 (green) and BEST1 (red) in cultured RPE cells treated with DMSO, erlotinib alone, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. (H) Overview of the experimental workflow for ECM degradation assay. (I) Representative immunostaining images (upper) show the fluorescence intensity of fibronectin in cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Quantification of mean fluorescence intensity of FN1 across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. Representative brief field images (lower) show the distribution of cultured RPE cells treated with DMSO, erlotinib, or erlotinib in combination with an anti-CHI3L1 neutralizing antibody. Scale bars: 100 μm. Quantification of particles average size across different groups. Data represent mean ± SD; n = 3; one-way ANOVA; ∗∗ p < 0.01; ∗∗∗ p < 0.001. Scale bars: 100 μm. (J) Schematic diagram showing potential mechanisms underlying EGFR inhibition-induced donor cell integration. See also .

    Article Snippet: Fibronectin (Green Fluorescent, HiLyte 488) , Cytoskeleton , FNR02.

    Techniques: Expressing, RNA Sequencing, Cell Culture, Suspension, Control, Immunostaining, Degradation Assay, Fluorescence, Inhibition

    Journal: Cell Reports Medicine

    Article Title: EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation

    doi: 10.1016/j.xcrm.2026.102963

    Figure Lengend Snippet:

    Article Snippet: Fibronectin (Green Fluorescent, HiLyte 488) , Cytoskeleton , FNR02.

    Techniques: Control, Virus, Recombinant, Modification, Isolation, Proliferation Assay, Single Cell, Knockdown, Software